Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage pharmaceutical company whose news flow centers on the development of next-generation pain and central nervous system therapeutics that incorporate built-in abuse and overdose protection. Company updates frequently highlight progress across its proprietary TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) platforms, which are designed to create tamper-resistant prodrugs and overdose-protected medications.
Investors and healthcare observers following ENSC news can expect regular coverage of clinical milestones for PF614, the company’s TAAP™ extended-release oxycodone analogue for moderate to severe pain, including pivotal Phase 3 trial activities and regulatory interactions with the U.S. Food and Drug Administration. News items also describe the evolution of PF614-MPAR, which combines PF614 with MPAR® overdose protection and is advancing under FDA Breakthrough Therapy designation with support from multi-year NIDA grants.
Beyond pain management, Ensysce news includes developments in its ADHD pipeline, such as patent notices for PF8026, an immediate-release amphetamine prodrug that uses TAAP™ and MPAR® technologies to address stimulant abuse and overdose risk. Updates on PF9001, the company’s lead opioid use disorder candidate supported by a HEAL grant, also appear in the company’s communications.
Additional ENSC news covers intellectual property achievements extending MPAR® patent protection, federal grant awards, symposium presentations at major pain conferences, and financing transactions such as preferred stock offerings and registered direct offerings disclosed via SEC filings and press releases. This news page aggregates these announcements so readers can track Ensysce’s clinical, regulatory, intellectual property, and capital markets developments in one place.
Ensysce Biosciences has successfully completed a private placement for $15 million through senior secured convertible notes and warrants. The latest funding round closed on November 5, 2021, with $10 million raised. The convertible notes have a conversion price of $5.87, and the accompanying warrants allow for the purchase of common stock at $7.63. Funds will support the advancement of clinical trial programs, including critical studies related to opioid abuse prevention. This financing strengthens Ensysce's commitment to developing safer prescription drugs.
Ensysce Biosciences has appointed Linda Pestano, PhD, as Chief Development Officer effective October 15, 2021. Dr. Pestano brings over 20 years of experience in drug development and has worked on therapies for various indications. CEO Dr. Lynn Kirkpatrick highlighted her expertise as a boon for advancing their opioid products and addressing concerns in the opioid crisis. Ensysce is focused on developing safer prescription drugs through its proprietary platforms aimed at reducing abuse and overdose.
Ensysce Biosciences has secured a $15 million investment through a securities purchase agreement involving senior secured convertible notes and warrants. The initial $5 million was funded on September 24, 2021. The notes, convertible at $5.87, mature in 21 months, bearing 5% interest. Proceeds will support clinical programs, including studies on opioid treatment. CEO Dr. Lynn Kirkpatrick highlighted this financing as essential for combating the opioid crisis.
Ensysce Biosciences has commenced a second clinical study of PF614, a trypsin-activated opioid designed to deter abuse, with the first cohort enrolled on September 7, 2021. This Phase 1b trial will evaluate PF614's pharmacokinetics and safety, comparing it to OxyContin. The study aims to advance understanding of PF614's potential as a safer pain management option, contributing to solutions for the opioid crisis. Ensysce's innovative approach aligns with pressing healthcare needs, focusing on effective treatments for chronic pain while minimizing abuse risks.
Ensysce Biosciences (NASDAQ:ENSC) has scheduled participation in multiple key industry conferences throughout September 2021. CEO Dr. Lynn Kirkpatrick will present at the 10th Annual Gateway Conference on September 8. Additionally, Ensysce will sponsor a symposium at PAINWeek 2021 on September 9, focusing on next-generation opioids with abuse protection. The company will also engage in one-on-one meetings during Lake Street's Best Ideas Growth Conference on September 14. Ensysce aims to utilize its proprietary technologies to reduce prescription drug abuse and overdose risks.
Ensysce Biosciences (NASDAQ: ENSC, OTC: ENSCW) is sponsoring a symposium at PAINWeek 2021 on September 9, focusing on innovative opioid solutions with built-in abuse and overdose protection. Chaired by Dr. Jeffrey Gudin, the event will showcase advancements in pain management amid the ongoing opioid crisis. Dr. Lynn Kirkpatrick, CEO, emphasizes the company's mission to transform pain treatment and combat prescription drug abuse through proprietary platforms. Ensysce aims to offer safer opioid alternatives to improve patient care and reduce societal impacts.
Ensysce Biosciences reported Q2 2021 financial results, highlighting a successful merger with Leisure Acquisition Corp., providing access to $60 million in capital. Cash reserves reached $8 million. Key programs include PF614 entering Phase 1b and PF614-MPAR™ receiving IND from the FDA. Federal grant funding dropped to $0.4 million from $1.8 million YoY. Net loss increased to $1 million from $0.7 million. The company aims to address opioid use and pain management through its innovative drug platforms.
Ensysce Biosciences has completed its merger with Leisure Acquisition Corp, with trading of its common stock as ENSC and warrants as ENSCW starting July 1, 2021. This merger allows Ensysce to enhance its mission of reducing prescription drug abuse through its specialized technology platforms, TAAP and MPAR. The company’s PF614 and PF614-MPAR products, aimed at minimizing the abuse potential of oxycodone, are entering mid-stage clinical development. The leadership is optimistic about the merger's potential to accelerate clinical programs and expand their product pipeline.